Olmesartán/Amlodipino Sandoz (Olmesartan Medoxomil, Amlodipine Besilate)

Olmesartan/Amlodipine is a fixed‑dose antihypertensive that acts on the renin‑angiotensin system and vascular smooth‑muscle tone.

• Hypertension: helps achieve target blood pressure when monotherapy is insufficient.
• Hypertension with concomitant edema: reduces fluid retention while controlling pressure.
• High‑risk cardiovascular patients: contributes to overall risk reduction as part of a comprehensive treatment plan.

• Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while amlodipine besilate inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect lowers systemic vascular resistance and blood pressure without significant impact on heart rate.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness, especially after standing.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

• Angio‑edema: swelling of face, lips, tongue or airway.
• Severe hypotension: markedly low blood pressure causing fainting.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Acute kidney injury: sudden decline in renal function.
• Myocardial infarction: rare occurrence of heart attack.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

When prescribing Olmesartan/Amlodipine, clinicians should consider patient‑specific factors and monitor for adverse events.

• Renal impairment: adjust monitoring and avoid rapid dose escalation.
• Hepatic disease: use with caution and assess liver function periodically.
• Pregnancy: contraindicated; drug may harm fetal development.
• Concomitant potassium‑sparing diuretics: monitor serum potassium levels.
• Elderly patients: start at lower dose and observe for orthostatic symptoms.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan/Amlodipine may interact with several drug classes; careful review is recommended.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade: concurrent ACE inhibitors or ARBs increases risk of hyperkalaemia and renal impairment.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise amlodipine levels.
• Lithium: increased risk of lithium toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Diuretics: additive blood‑pressure lowering effect; monitor electrolytes.
• Simvastatin: increased statin exposure; consider dose adjustment.